Introduction

Factor XII (FXII), a key player in blood coagulation and inflammation, has emerged as a promising therapeutic target. Researchers have developed a nanoantibody (Nb) targeting FXII with high affinity and neutralizing activity.

Anti-thrombotic effects of Nanoantibody

In mouse models, this Nb-Fc fusion protein shows significant anti-thrombotic effects. In a carotid artery thrombosis model, it prolonged the time to occlusion and reduced occlusion rates. Importantly, it did not affect tail bleeding time, indicating safe hemostatic function.

Moreover, the nanoantibody showed potential in reducing thrombosis and organ damage. Combined with heparin, it significantly decreased thrombus deposition on oxygenator membranes and microvascular thrombosis in vital organs.

It also targeted inflammatory responses. In a vasculitis model, it reduced skin inflammation, neutrophil infiltration, and myeloperoxidase levels. The nanoantibody selectively inhibited neutrophil migration in vitro and in vivo, suggesting a mechanism involving neutrophil activity modulation.

Human blood microfluidic analysis further confirmed its efficacy, reducing platelet aggregation, fibrin deposition, and neutrophil adhesion. These findings pave the way for a novel therapeutic approach to thrombosis and inflammation-related diseases, offering hope for better patient outcomes.

Conclusion

In summary, the nanoantibody Nb-Fc targeting FXII exhibits significant anti-thrombotic and anti-inflammatory effects, providing a new strategy for the treatment of thrombosis and inflammation-related diseases. This research brings new hope to the field of medical science and promises better treatment outcomes for patients with related conditions.

Yaohai Bio-Pharma is also actively seeking institutional or individual global partners and offers the most competitive compensation in the industry. If you have any questions, please feel free to contact us: [email protected]

For more details about Yaohai Bio-Pharma, please kindly refer to the website: www.yaohaibio-pharma.com